The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...

At present no definitive medical treatment exists for acute pancreatitis. [9,10] Pirenzepine has shown encouraging positive responses and a low incidence of adverse effects when used to treat ...

Anticholinergics are competitive inhibitors of acetylcholine at muscarinic receptors (mainly the M3 receptor subtype), and they thereby inhibit involuntary bladder contractions. [19] The effective ...

An early study with chimeric receptors between the alpha2c-adrenergic receptor and m3-muscarinic receptor suggested the possible heterodimerization between GPCR types. Direct evidence for GPCR ...

Our recent work (McQuail & Burk, 2006) suggests that cholinergic muscarinic receptors, particularly the muscarinic M1 receptor, are important for mediating the effects of the cortical acetylcholine on ...

Our recent work (McQuail & Burk, 2006) suggests that cholinergic muscarinic receptors, particularly the muscarinic M1 receptor, are important for mediating the effects of the cortical acetylcholine on ...

Researchers from Maplight Therapeutics Inc. presented preclinical data for the investigational muscarinic M1/M4 receptor agonist ML-007, being evaluated for the treatment of neuropsychiatric disorders ...

An antipsychotic drug approved last month by the FDA changes that. It triggers muscarinic receptors instead of dopamine receptors. The drug is the result of a chance scientific finding ...

The latest candidate to move into phase 2 is NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is the most advanced candidate in a $2.6 billion alliance with Neurocrine signed ...